Vytorin Fallout Continues: GAO Questions FDA's Handling Of Surrogate Endpoints
This article was originally published in The Pink Sheet Daily
Executive Summary
"The agency has taken a passive approach to enforcing confirmatory study requirements," according to the report, which calls on FDA to issue guidance on when it would pull a drug with problems.
You may also be interested in...
Abbott's Niaspan/Zetia Head-To-Head Trial Deemed Too Small And Inconclusive
However, some physicians, such as Cleveland Clinic cardiologist Steve Nissen, argue the results support other, larger trials.
Abbott's Niaspan/Zetia Head-To-Head Trial Deemed Too Small And Inconclusive
However, some physicians, such as Cleveland Clinic cardiologist Steve Nissen, argue the results support other, larger trials.
Postmarketing Studies Face Continued Scrutiny Despite Cleaned-Up Database
Drug makers that have put off starting post-market studies under FDA oversight can no longer count on the agency's messy database to provide cover for their dawdling